Clinical trials: Recurrent Medulloblastoma
Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia.
- Conditions
- Blastic Phase Chronic Myelogenous Leukemia, Childhood Central Nervous System Germ Cell Tumor, Childhood Choroid Plexus Tumor, Childhood Chronic Myelogenous Leukemia
- Trial name
- NCT00053963
- Testing
- romidepsin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Central Nervous System Neoplasms, Medulloblastoma
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
This study will assess the efficacy, safety and tolerability of pomalidomide in children and young adults aged 1 to < 21 years with recurrent or progressive primary brain tumors in one of four primary brain tumor types…
- Trial name
- NCT03257631
- Testing
- Pomalidomide
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 53 people
- Sponsor
- Celgene
Recurrent Medulloblastoma, Recurrent Ependymoma
131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma.
- Trial name
- NCT04743661
- Testing
- Irinotecan, Temozolomide, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
RATIONALE: Drugs used in chemotherapy, such as VNP40101M, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00098761
- Testing
- laromustine
- Where
- 10 sites in United States
- Volunteers
- 42 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors, Head and Neck Cancer
Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Head and Neck Cancer, Lymphoma
- Trial name
- NCT00007982
- Testing
- filgrastim, carmustine, cisplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Lymphoma
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00544284
- Testing
- bortezomib, temozolomide, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Phase I trial to study the effectiveness of O6-benzylguanine and carmustine in treating children who have refractory CNS tumors.
- Trial name
- NCT00003765
- Testing
- O6-benzylguanine, carmustine
- Where
- 56 sites in United States, Australia and 1 more
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
CNS Malignancies, Medulloblastoma Recurrent
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
This clinical trial is studying a drug called SGT-53 along with radiation and another drug called Nivolumab. It's for children with brain tumors that have come back, gotten worse, or didn't get better with earlier treatments.
- Conditions
- CNS Malignancies, Medulloblastoma Recurrent, ATRT Recurrent, Pineoblastoma
- Trial name
- JACOB (NCT07017816)
- Testing
- SGT-53, hypofractionated radiotherapy with immunotherapy, Nivolumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Children's National Research Institute
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)
A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma
The purpose of this study is to assess the safety and tolerability profile of TB-403 (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects with relapsed or refractory Medulloblastoma.
- Trial name
- NCT02748135
- Testing
- TB-403 20mg/kg, TB-403 50mg/kg, TB-403 100mg/kg
- Where
- 10 sites in United States
- Volunteers
- 18 people
- Sponsor
- Oncurious NV
Osteosarcoma, Medulloblastoma
A Study of Pemetrexed in Children With Recurrent Cancer
To determine the response rate of pemetrexed given every 21 days for the treatment of children with relapsed or refractory osteosarcoma, Ewing's sarcoma/peripheral primitive neuroectodermal tumors (PNET), rhabdomyosarcoma…
- Conditions
- Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease)
- Trial name
- NCT00520936
- Testing
- pemetrexed
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Recurrent Childhood Medulloblastoma
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
This phase I trial is studying the side effects and best dose of GDC-0449 in treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment.
- Trial name
- NCT00822458
- Testing
- vismodegib, laboratory biomarker analysis, pharmacological study
- Where
- 9 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Glioma, Medulloblastoma
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Background: About 90,000 new cases of brain and spinal cord tumors are diagnosed annually in the United States. Most of these tumors are benign; however, about 30% are malignant, and 35% of people with malignant tumors in the…
- Conditions
- Glioma, Medulloblastoma, Ependymoma, Glioblastoma
- Trial name
- NCT06161519
- Testing
- PLX038
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma, Malignant Glioma
Cytomegalovirus (CMV) RNA-Pulsed Dendritic Cells for Pediatric Patients and Young Adults With WHO Grade IV Glioma, Recurrent Malignant Glioma, or Recurrent Medulloblastoma
The purpose of this study is to determine the feasibility and safety of administering CMV RNA-pulsed dendritic cells (DCs), also known as CMV-DCs, to children and young adults up to 35 years old with nWHO Grade IV glioma…
- Conditions
- Glioblastoma, Malignant Glioma, Medulloblastoma Recurrent, Pediatric Glioblastoma Multiforme
- Trial name
- ATTAC-P (NCT03615404)
- Testing
- CMV-DCs with GM-CSF, Td (tetanus toxoid)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Gary Archer Ph.D.
Relapsed Solid Tumor, Refractory Solid Tumor
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
The study's purpose is to see if the drug, abemaciclib, is safe and effective when given with other drugs to kill cancer cells. The study is open to children and young adults with solid tumors, including neuroblastoma, that did…
- Trial name
- NCT04238819
- Testing
- Abemaciclib, Irinotecan, Temozolomide
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Medulloblastoma, Glioblastoma Multiforme
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer.
- Conditions
- Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS
- Trial name
- NCT04978727
- Testing
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
- Where
- 14 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery or radiation therapy may shrink the tumor so that it can be removed…
- Trial name
- NCT00025077
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy…
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Trial name
- NCT02095132
- Testing
- Adavosertib, Irinotecan Hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
SU5416 in Treating Children With Recurrent or Progressive Brain Tumors
RATIONALE: SU5416 may stop the growth of brain cancer cells by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the safety of delivering SU5416 in children who have recurrent or progressive brain tumors.
- Trial name
- NCT00006247
- Testing
- semaxanib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Pediatric Brain Tumor Consortium